Cytek Q2 2025 revenue $45.6M (-2% YoY); narrows 2025 guidance to $196-205M

Cytek Biosciences, Inc.

Revenue $45.6M, down 2% YoY; net loss $5.6M vs $10.4M loss in Q2 2024.
Adjusted EBITDA $1.3M (down from $2.9M); operating loss $10.6M vs $8.5M.
Installed base grew to 3,295 instruments (146 new units); launched Aurora Evo system.
Recurring revenue up 16% YoY; repurchased $4.5M in stock during Q2.
2025 revenue guidance narrowed to $196-205M (flat to -2% growth over 2024).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.